Clinical Trials Browser

Phase NA × Rituximab × 90 days × Clear all

NCT07299331 2025-12-23

Zanubrutinib, Rituximab, and Lenalidomide in the First-Line Treatment of Marginal Zone Lymphoma

Phase NA Not yet recruiting

Lymphoma, B-Cell, Marginal Zone